How does NGS address the changes that cancer treatment is undergoing, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?

How does NGS address the changes that cancer treatment is undergoing, toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?

In what important ways does NGS address the fundamental changes that systemic cancer treatment is undergoing, i.e., toward the use of molecularly targeted drugs prescribed to selected subsets of patients across multiple tumor types?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Yilong Wu, MD

Yilong Wu, MD

Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China